William Blair analyst Alexandra Ramsey has maintained their bullish stance on AKTS stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alexandra Ramsey’s rating is based on Aktis Oncology’s differentiated position in a rapidly expanding radiopharmaceuticals market, which she estimates at roughly $35 billion, and its proprietary miniprotein platform that blends advantages of small molecules and antibodies to balance efficacy and safety. She notes that this technology can be applied to many validated targets, giving Aktis a broad opportunity set across multiple cancer indications.
Alexandra Ramsey has given her Buy rating due to a combination of clinically and commercially de-risked programs and attractive pipeline design, including the use of actinium-225 to induce potent double-stranded DNA damage and reduce resistance risk. She highlights that lead asset AKY-1189, aimed at nectin-4, and AKY-2519, aimed at B7-H3, both address widely expressed tumor antigens, creating multiple paths to success and reinforcing her conviction that Aktis can emerge as a leader in radiopharmaceuticals.
According to TipRanks, Ramsey is ranked #8514 out of 12188 analysts.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $34.00 price target.